Nurix Therapeutics, Inc.
NRIX
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.7B
$25.78
▼ -1.64%
P/E
-7.47
Mkt Cap
$2.7B
52-Wk Range
$8.20–$28.23
52-Week Range
$8.20 - $28.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 187.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary protein degradation platform enabling selective target elimination
- Strategic partnerships with Gilead Sciences and Sanofi providing validation and resources
- Oral bioavailability of lead candidates improving patient accessibility
- Differentiated approach to immuno-oncology through CBL-B inhibition
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Strong growth ahead
Clinical advancement of BTK degraders in relapsed/refractory B-cell malignancies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+47.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NRIX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 8, 2026
JUL 9, 2026
Reported EPS of -$0.81 vs -$0.73 consensus (-11.0% surprise). Revenue of $9.0M vs $15.3M expected (-40.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-11.0%
Revenue trend · last 8Q
—
-12%
+11%
+264%
-37%
+2%
-66%
-79%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$12.6M
$13.3M
$18.5M
$44.1M
$7.9M
$13.6M
$6.3M
$9.0M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-990.1%
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Jul 28, 2026
vs Industry
How NRIX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related